Background & Aims Biopsy-confirmed liver fibrosis is a prognostic factor for patients with
nonalcoholic fatty liver disease (NAFLD). We performed a systematic review to quantify the …

Abstract Background & Aims Fibrosis is the strongest predictor for long‐term clinical
outcomes among patients with non‐alcoholic fatty liver disease (NAFLD). There is growing …

Background & Aims Fibrosis is a key determinant of clinical outcomes in nonalcoholic fatty
liver disease (NAFLD), but time-dependent risk of mortality has not been reported in …

There is an unmet need for high‐quality liquid biomarkers that can safely and reproducibly
predict the stage of fibrosis and the outcomes of chronic liver disease (CLD). The …

Whereas diagnostic tests help detect the cause of signs and symptoms, prognostic tests
assist in evaluating the probable course of the disease and future outcome. Studies to …

In the last 20 years, noninvasive serum biomarkers to identify liver fibrosis in patients with
non-alcoholic fatty liver disease (NAFLD) have been developed, validated against liver …

This review evaluates the ability of the fibrosis index based on four factors (FIB-4) identifying
fibrosis stages, long-time prognosis in chronic liver disease, and short-time outcomes in …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease.
Nonalcoholic steatohepatitis (NASH) is an advanced form of NAFLD can progress to liver …

Fibrosis, stiffening and scarring of an organ/tissue due to genetic abnormalities,
environmental factors, infection, and/or injury, is responsible for> 40% of all deaths in the …

Background & Aims Liver steatosis may occur concomitantly in patients with chronic
hepatitis B infection (CHB) and is implicated in increased morbidity and mortality. Hepatitis B …